On August 12, 2020 NOXXON Pharma N.V. (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), reported that its poster titled "Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer" has been selected for presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Virtual Congress 2020 (Press release, NOXXON, AUG 12, 2020, View Source [SID1234563532]). The ESMO (Free ESMO Whitepaper) Virtual Congress with accompanying satellite programs will be held between September 14 and October 18, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on the ESMO (Free ESMO Whitepaper) website in the On-Demand E-Poster Display section and on the NOXXON website as of Thursday, September 17, 2020. The abstract will be published online via the ESMO (Free ESMO Whitepaper) website on Monday, September 14, 2020.